Jeanmarie Guenot is a senior executive officer and president of Amphivena Therapeutics. Dr. Guenot is an alma mater of the University of Pennsylvania and the University of California. She is also an alumnus of the high-profile University of California, San Fransisco where she took a course in legal studies. Dr. Guenot’s background is medicinal and physical chemistry, which makes her an expert in biotechnology. She is famous for starting and rebuilding pharmaceutical companies and has worked in both the private and public sector.
Dr. Guenot’s career and achievements
Dr. Guenot’s career began over two decades ago at Atlas Venture. Throughout her tenure in this company, she was in charge of managing venture capital investments. For years, she has worked for various companies, such as Hoffmann-La Roche, PDL Biopharma, Guenot LLC., and SKS Ocular, LLC. Aside from conducting managerial duties, Dr. Jeanmarie Guenot is involved in research and has worked as a scientist for six years. She is the founder of SKS Ocular LLC and Guenot LLC. SKS Ocular LLC is an ophthalmic company launched in 2009. This biotechnology firm pioneers in the development ocular drug delivery technologies. SKS Ocular LLC also conducts research on therapeutics for macular degeneration, ocular inflammation, and glaucoma. Dr. Guenot serves as the managing partner of this firm. For years, she has managed to steer this company into focusing on dry AMD. While working for Hoffmann-La Roche on BusinessWire.com, she facilitated mergers & acquisitions, licensing of drugs, and management of commercial product portfolios.
Expertise in drug development
JeanMarie Guenot takes pride in being one of the lead executives who negotiated a $800 million business deal. This deal on amphivena.com was about co-commercialization and later co-development of Biogen Idec-PDL 50:50. This transaction resulted in the launch of clinical trials for Phase 2 cancer and autoimmune disease drugs and recruitment of three candidates. The key players involved were two companies at https://www.takeda.com/news/2017/20170111_7659.html: Hoffmann-La Roche and Biogen Idec/PDL. Dr. Guenot is responsible for licensing the ophthalmic indication for Ophthotech, an oncology drug. She has experience in management of projects in the field of autoimmune diseases, cardiovascular, neurology, oncology, and ophthalmic disease conditions.